Established in 1964, New York Blood Center (NYBC) is one of the largest community-based, nonprofit blood collection and distribution organizations in the United States. Through the integrated efforts of our blood services operations, NYBC annually provides some one million blood components to nearly 200 hospitals throughout New York City, New Jersey, Hudson Valley, Long Island, Connecticut, and Pennsylvania.
NYBC remains dedicated to providing the safest, highest quality transfusion products to patients in our communities, including cancer and surgery patients, accident and burn victims, AIDS and sickle cell anemia patients, transplant recipients, hemophiliacs, and many others. NYBC also has a growing medical agenda. Our Clinical Services Program provides state-of-the-art transfusion services and highly specialized patient care procedures each year at hospitals in the tri-state area. Our Hemophilia Services Program ensures local hemophilia patients have access to the 24-hour-a-day, 7-day-a-week care, counseling, and clotting factors they require.
NYBC also serves as the New York area registry for the National Marrow Donor Program. Since 1989, NYBC has helped register close to 240,000 potential bone marrow donors, and NYBC has helped over 1,400 donors donate bone marrow or stem cells to patients in need.
We are home to the National Cord Blood Program at the Howard P. Milstein Cord Blood Center (NCBP), the world's oldest and largest public cord blood bank. Since its founding, NYBC has banked more than 60,000 cord blood units. In 2011, NYBC became the first public cord blood bank in the world to receive NetCord-FACT accreditation (2003) and licensure of one of its stem cell products—HEMACORD™ (hematopoietic progenitor cells, cord blood).
NYBC’s Lindsley F. Kimball Research Institute continues to lead the way in blood research that saves lives, attracting the highest caliber research scientists integrating basic, clinical, translational, and epidemiological research. NYBC researchers have paved the way for new blood-related products, techniques, and therapies as well as numerous landmark patents. LFKRI investigators developed the solvent/detergent method for the inactivation of viruses in plasma as well as a practical screening test for hepatitis B and an affordable hepatitis B vaccine. LFKRI research on the plasma proteins fibrinogen and fibrin had a major impact on the understanding of hemostasis and thrombosis.
NYBC corporate publications reflect our commitment to standards, policies, and procedures that ensure we continue to achieve our lifesaving mission in the communities we serve.